UnknownNot Applicable

Moderate Hypofractionated Radiotherapy for Lung Cancer

China60 participantsStarted 2016-11-01

Plain-language summary

The purpose of this study is to evaluate the incidences of Grade III and above radiation-reduced esophagitis and radiation-reduced pneumonia of patients with advanced lung cancer treated with moderate hypofractionated (3Gy/f) radiotherapy, and their predictors. Efficacies are also evaluated.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Patients with previously untreated advanced lung cancer were recruited, who were confirmed pathologically or cytologically.
. The Karnofsky performance status (KPS) score ≥60.
. The expected survival time was≥3 months.
. The laboratory examination results showed a neutrophil count ≥2.0 × 109, a hemoglobin level ≥100 g/L, a platelet count ≥100 × 109, and enough liver and kidney functions.
. The patients did not show abnormal electrocardiogram (ECG) results.
. They did not have other combined diseases that required hospitalization.
. Informed consent required before enrollment.

Exclusion criteria

. Patients who were pregnant or breastfeeding.
. Patients who had another malignant tumor history (with the exception of patients with cervical carcinoma in situ and non-malignant melanoma skin cancer that had been clinically cured for at least 5 years), could not receive concurrent chemotherapy due to medical reasons.
. Superior vena cava syndrome.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Incidence of grade III and above radiation-reduced esophagitis

Timeframe: three years

Incidence of grade III and above radiation-reduced pneumonitis

Timeframe: three years

Trial details

NCT IDNCT03833193

SponsorNorth China Petroleum Bureau General Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-05-01

Contact for this trial

QIANG LIN, Dr

+86-177-177-37955 billhappy001@163.com

View on ClinicalTrials.gov More Lung Cancer trials